Evocalcet (BioDeep_00000802621)
代谢物信息卡片
化学式: C24H26N2O2 (374.1994176)
中文名称: 依伏卡塞
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(C1=CC=CC2=CC=CC=C21)NC3CCN(C3)C4=CC=C(C=C4)CC(=O)O
InChI: InChI=1S/C24H26N2O2/c1-17(22-8-4-6-19-5-2-3-7-23(19)22)25-20-13-14-26(16-20)21-11-9-18(10-12-21)15-24(27)28/h2-12,17,20,25H,13-16H2,1H3,(H,27,28)/t17-,20+/m1/s1
描述信息
C78275 - Agent Affecting Blood or Body Fluid > C2136 - Malignancy-Associated Hypercalcemia Inhibitor
同义名列表
1 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- KEGGdrug: D11063
- PubChem: 71242808
- DrugBank: DB12388
- ChEMBL: CHEMBL4297621
- CAS: 870964-67-3
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Jing Xie, Xueying Li, Yang Chen, Ming Chen, Nan Mao, Junming Fan. Efficacy and safety of evocalcet in treatment of secondary hyperparathyroidism in chronic kidney disease on hemodialysis patients: A protocol for a systematic review and meta-analysis.
Medicine.
2020 Nov; 99(46):e22566. doi:
10.1097/md.0000000000022566. [PMID: 33181644] - Yasuhiro Takeuchi, Yuichi Nishida, Yuichiro Kondo, Yasuo Imanishi, Seiji Fukumoto. Evocalcet in patients with primary hyperparathyroidism: an open-label, single-arm, multicenter, 52-week, dose-titration phase III study.
Journal of bone and mineral metabolism.
2020 Sep; 38(5):687-694. doi:
10.1007/s00774-020-01097-y. [PMID: 32274572] - Suetonia C Palmer, Dimitris Mavridis, David W Johnson, Marcello Tonelli, Marinella Ruospo, Giovanni F M Strippoli. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2020 09; 76(3):321-330. doi:
10.1053/j.ajkd.2020.02.439. [PMID: 32475604] - Naoto Hamano, Yuichi Endo, Takehisa Kawata, Masafumi Fukagawa. Development of evocalcet for unmet needs among calcimimetic agents.
Expert review of endocrinology & metabolism.
2020 09; 15(5):299-310. doi:
10.1080/17446651.2020.1780911. [PMID: 32552012] - Tadao Akizawa, Kazuaki Ikejiri, Yuichiro Kondo, Yuichi Endo, Masafumi Fukagawa. Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism.
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
2020 Jun; 24(3):248-257. doi:
10.1111/1744-9987.13434. [PMID: 31486206] - Mariko Sakai, Shin Tokunaga, Mika Kawai, Miki Murai, Misaki Kobayashi, Tetsuya Kitayama, Satoshi Saeki, Takehisa Kawata. Evocalcet prevents ectopic calcification and parathyroid hyperplasia in rats with secondary hyperparathyroidism.
PloS one.
2020; 15(4):e0232428. doi:
10.1371/journal.pone.0232428. [PMID: 32343734] - Kazuhiko Tsuruya, Ryutaro Shimazaki, Masafumi Fukagawa, Tadao Akizawa. Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients.
Clinical and experimental nephrology.
2019 Jun; 23(6):739-748. doi:
10.1007/s10157-019-01692-y. [PMID: 30955188] - Keitaro Yokoyama, Ryutaro Shimazaki, Masafumi Fukagawa, Tadao Akizawa. Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis.
Scientific reports.
2019 04; 9(1):6410. doi:
10.1038/s41598-019-42017-z. [PMID: 31015494] - Takashi Shigematsu, Ryutaro Shimazaki, Masafumi Fukagawa, Tadao Akizawa. Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients.
Clinical and experimental nephrology.
2019 Feb; 23(2):258-267. doi:
10.1007/s10157-018-1635-6. [PMID: 30159688] - Shin Tokunaga, Yuichi Endo, Takehisa Kawata. [Pharmacological and clinical profiles of a novel calcimimetic, evocalcet (ORKEDIA®)].
Nihon yakurigaku zasshi. Folia pharmacologica Japonica.
2019; 154(1):35-43. doi:
10.1254/fpj.154.35. [PMID: 31308348] - Masafumi Fukagawa, Ryutaro Shimazaki, Tadao Akizawa. Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism.
Kidney international.
2018 10; 94(4):818-825. doi:
10.1016/j.kint.2018.05.013. [PMID: 30049473]